Inloggad som:
M18-868-Teliso
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
M18-868-Teliso
Phase 3, open-label, randomized, controlled, global study in subjects with c-Met overexpressing (c- Met+), EGFR wildtype, locally advanced/metastatic non-squamous NSCLC that has progressed after standard of care therapy.
Phase 3, open-label, randomized, controlled, global study in subjects with c-Met overexpressing (c- Met+), EGFR wildtype, locally advanced/metastatic non-squamous NSCLC that has progressed after standard of care therapy.
PLACEHOLDER
Mer information om studien för vårdgivare
Studien ändrades senast av: studyjohanna (2023-03-18)